[The use of mildronate and trental in treating disorders of hemorheology and the intracardiac hemodynamics in patients with chronic obstructive bronchitis].
Overall ninety patients with chronic obstructive bronchitis presenting with signs of pulmonary-cardiac insufficiency (CPI) were studied by static radionuclide ventriculography with pertechnetate and rotation viscosimetry before and after a 14-day course of treatment. All the patients received basic treatment with cardiac glycosides on a differential basis depending upon CPI severity. Those patients having been prescribed mildronate additionally in a daily dose of 10 mg/kg body mass demonstrated improvement in left ventricular performance: the total and regional ejection fractions got increased, with the end-diastolic and end-systolic volumes having gotten reduced. Those patients receiving mildronate combined with thrental at a daily dose of 7-8 mg/kg body mass showed improvement in rheologic properties of blood as well as in intracardiac haemodynamics. At the same time, the right and left ventricles of the heart improved their performance, with their dysfunction having been lessened: the total and regional ejection fractions appeared to be increased, the end-diastolic and end-systolic volumes reduced, the amplitude-time characteristics of the processes of ejection and filling of the ventricles of the heart were found out to get better.
Sakharchuk
I I
II
Il'nyts'kyĭ
R I
RI
D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D008763:Methylhydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011660:Pulmonary Heart Disease / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002317:Cardiovascular Agents; D008763:Methylhydrazines; D014665:Vasodilator Agents; C050147:3-(2,2,2-trimethylhydrazine)propionate; D010431:Pentoxifylline